Evidence map›Paper›PMID 25260254›Full record

ArticleToxicon : official journal of the International Society on Toxinology2014

A tripartite cocktail of chimeric monoclonal antibodies passively protects mice against ricin, staphylococcal enterotoxin B and Clostridium perfringens epsilon toxin.

Erin K Sully, Kevin Whaley, Natasha Bohorova, Ognian Bohorov, Charles Goodman, Do Kim, Michael Pauly, Jesus Velasco, Frederick W Holtsberg, Eric Stavale and 5 more

Abstract read
In one paragraph

Article in Toxicon : official journal of the International Society on Toxinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Erin K SullyDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Kevin WhaleyMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA.
Natasha BohorovaMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA.
Ognian BohorovMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA.
Charles GoodmanMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA.
Do KimMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA.
Michael PaulyMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA.
Jesus VelascoMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA.
Frederick W HoltsbergIntegrated BioTherapeutics, Gaithersburg, MD, USA.
Eric StavaleIntegrated BioTherapeutics, Gaithersburg, MD, USA.
M Javad AmanIntegrated BioTherapeutics, Gaithersburg, MD, USA.
Chandra TanguduDepartment of Veterinary Sciences, Iowa State University, USA.
Francisco A UzalUniversity of California, Davis, USA.
Nicholas J MantisDivision of Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA; Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, NY, USA. Electronic address: nicholas.mantis@health.ny.gov.
Larry ZeitlinMapp Biopharmaceutical, Inc., 92121 San Diego, CA, USA. Electronic address: larry.zeitlin@mappbio.com.

Funding

Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT)U01AI082276 · NIAID · MAPP BIOPHARMACEUTICAL, INC. · PI ZEITLIN, LARRY · 2009 to 2013
$10.0M
An Antibody Immunoprotectant for Category B ToxinsR01AI098774 · NIAID · MAPP BIOPHARMACEUTICAL, INC. · PI ZEITLIN, LARRY · 2012 to 2016
$6.2M
Training in Biodefense and Emerging Infectious DiseaseT32AI055429 · NIAID · WADSWORTH CENTER · PI MCDONOUGH, KATHLEEN A · 2004 to 2014
$2.2M
NIAID NIH HHS R01 AI098774NIAID NIH HHS R01AI098774NIAID NIH HHS T32 AI055429NIAID NIH HHS U01 AI082276NIAID NIH HHS U01AI082276
6 · The paper itself

Abstract

Due to the fast-acting nature of ricin, staphylococcal enterotoxin B (SEB), and Clostridium perfringens epsilon toxin (ETX), it is necessary that therapeutic interventions following a bioterrorism incident by one of these toxins occur as soon as possible after intoxication. Moreover, because the clinical manifestations of intoxication by these agents are likely to be indistinguishable from each other, especially following aerosol exposure, we have developed a cocktail of chimeric monoclonal antibodies that is capable of neutralizing all three toxins. The efficacy of this cocktail was demonstrated in mouse models of lethal dose toxin challenge.

Indexed as

AnimalsAntibodies, MonoclonalBacterial ToxinsBioterrorismEnterotoxinsFemaleMiceMice, Inbred BALB CNeutralization TestsPoisoningRecombinant Fusion ProteinsRicinAntibodies, MonoclonalBacterial ToxinsClostridium perfringens epsilon-toxinenterotoxin B, staphylococcalEnterotoxinsRecombinant Fusion ProteinsRicinAntibodyBiodefenseTherapeuticToxin

Identifiers

PMID25260254
PMCPMC4248019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.